Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jan 2013

Bahce Idris, Smit Egbert F, Lubberink Mark, van der Veldt Astrid A M, Yaqub Maqsood, Windhorst Albert D, Schuit Robert C, Thunnissen Erik, Heideman Daniëlle A M, Postmus Pieter E, Lammertsma Adriaan A, Hendrikse N Harry

Abstract excerpt

PURPOSE: To evaluate whether, in patients with non-small cell lung carcinoma (NSCLC), tumor uptake of [(11)C]erlotinib can be quantified and imaged using positron emission tomography and to assess whether the level of tracer uptake corresponds with the presence of activating tumor EGF receptor (E...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbon Radioisotopes
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Multimodal Imaging

Share to Neoplasm Staging

Share to Positron-Emission Tomography

Share to Quinazolines

Share to Tomography, X-Ray Computed

Source

Identifiers

PMID: 23136193
DOI: 10.1158/1078-0432.CCR-12-0289

Genes

EGFR
EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23136193-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status.PMID 23136193Read ↗

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.Semantic proximity Read ↗

Assessment of simplified methods to measure 18F-FLT uptake changes in EGFR-mutated non-small cell lung cancer patients undergoing EGFR tyrosine kinase inhibitor treatment.Semantic proximity Read ↗

Pharmacokinetic analysis of 6-O-[18F]FEE for PET imaging of EGFR mutation.Semantic proximity Read ↗

The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations.Semantic proximity Read ↗

U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.Semantic proximity Read ↗

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.Semantic proximity Read ↗

18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis.Semantic proximity Read ↗

Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.